Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.
For patients with chronic migraine, onabotulinumtoxinA was shown to have a better outcome.
Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
Acupressure is not a beneficial adjunctive therapy to sodium valproate for the treatment of chronic migraine with aura.
More targeted injection sites may improve efficacy and the overall patient experience in chronic migraine.
The majority of centers follow protocols for administration of onabotulinumtoxinA.
A growing body of research indicates a number of shared features between chronic migraine and temporomandibular disorders.
In chronic migraine and medication overuse, those who frequently relapse into overuse after withdrawal have a worse clinical and psychological profile than patients who relapse less frequently.
During headache, patients with chronic migraine had greater activity in the right anterior hypothalamic region than patients with episodic or no migraine.
The study found a strong link between chronic migraine and psychological symptoms and beliefs that contribute to disability.
Remote electrical stimulation appears to have similar efficacy to standard drug treatments, including triptans.
Patients with chronic migraine and comorbidities incur nearly 2 times the health care costs incurred by patients with migraine alone.
A larger percentage of participants receiving CBT plus amitriptyline reached a 50% reduction in migraine frequency during treatment compared with HE plus amitriptyline.
Recovery time varies depending on which class of medication the patient is overusing.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
A 30% or greater decline in mean monthly moderate-to-severe headache days was met by 45.3 % (n=24) of patients treated with occipital nerve stimulation.
Patients in both groups were satisfied with their care.
Previous analysis showed that treatment reduced chronic migraine frequency.
Participants experienced a reduction in headache days as soon as 3 days post-treatment.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
Neurology Advisor Articles
- Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults
- Epilepsy's Mobility Problem: Advocating for Changes in Transportation Laws, Public Resources
- The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies
- Women With Epilepsy More Likely to Have Major Depressive Disorder
- Some Common Allergies Linked to Odds of Autism in Children
- CAPPRI Scale is Feasible for Assessing Health-Related Quality of Life in Diabetic Distal Sensorimotor Polyneuropathy
- Long-Term Type 1 Diabetes Associated With Cognitive Decline
- White Matter Hyperintensities in RCVS Vary Over Time
- Disrupted Thalamo-Striato-Hypothalamic Function May Serve as a Good Biomarker for Parkinson Disease
- Levetiracetam Effective as Episodic Migraine Prophylactic